Todd Bazemore, SEE REMARKS at Kala Pharmaceuticals, Inc. (KALA), sold 3,092 shares at $0.37 ($1K) on 2022-06-27, disclosed to the SEC on 2022-06-29.
Scheduled sale ($1k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KALA | SELL | 2025-06-04 | $13K | — | Filing → |
| KALA | SELL | 2025-01-07 | $15K | — | Filing → |
| KALA | SELL | 2024-06-27 | $22K | — | Filing → |